Logos Global Management L.P. 13F annual report
Logos Global Management L.P. is an investment fund managing more than $1.72 trillion ran by Derek Gould. There are currently 50 companies in Mr. Gould’s portfolio. The largest investments include IDEAYA Biosciences and Argenx Se, together worth $235 billion.
$1.72 trillion Assets Under Management (AUM)
As of 20th August 2024, Logos Global Management L.P.’s top holding is 3,400,000 shares of IDEAYA Biosciences currently worth over $119 billion and making up 6.9% of the portfolio value.
Relative to the number of outstanding shares of IDEAYA Biosciences, Logos Global Management L.P. owns less than approximately 0.1% of the company.
In addition, the fund holds 270,000 shares of Argenx Se worth $116 billion.
The third-largest holding is Merus N.V worth $101 billion and the next is Revolution Medicines Inc worth $93.1 billion, with 2,400,000 shares owned.
Currently, Logos Global Management L.P.'s portfolio is worth at least $1.72 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Logos Global Management L.P.
The Logos Global Management L.P. office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Derek Gould serves as the GC/CCO at Logos Global Management L.P..
Recent trades
In the most recent 13F filing, Logos Global Management L.P. revealed that it had opened a new position in
Argenx Se and bought 270,000 shares worth $116 billion.
The investment fund also strengthened its position in IDEAYA Biosciences by buying
1,900,000 additional shares.
This makes their stake in IDEAYA Biosciences total 3,400,000 shares worth $119 billion.
IDEAYA Biosciences dropped approximately 0.1% in the past year.
On the other hand, there are companies that Logos Global Management L.P. is getting rid of from its portfolio.
Logos Global Management L.P. closed its position in Immunocore Hldgs Plc on 27th August 2024.
It sold the previously owned 900,000 shares for $58.5 billion.
Derek Gould also disclosed a decreased stake in Sarepta Therapeutics Inc by 0.3%.
This leaves the value of the investment at $47.4 billion and 300,000 shares.
One of the largest hedge funds
The two most similar investment funds to Logos Global Management L.P. are Sageview Advisory and Quintet Private Bank (europe) S.A.. They manage $1.72 trillion and $1.72 trillion respectively.
Derek Gould investment strategy
Logos Global Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 54.5% of
the total portfolio value.
The fund focuses on investments in the United States as
44.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
12% of the total holdings value.
On the other hand, large-cap stocks make up only 2.0% of the portfolio.
The average market cap of the portfolio companies is close to $1.56 billion.
The complete list of Logos Global Management L.P. trades based on 13F SEC filings
These positions were updated on August 27th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| IDEAYA Biosciences, Inc. |
126.67%
3,400,000
|
$119,374,000,000 | 6.92% |
| Argenx Se |
Opened
270,000
|
$116,110,800,000 | 6.73% |
| Merus N.V |
Opened
1,700,000
|
$100,589,000,000 | 5.83% |
| Revolution Medicines Inc |
Opened
2,400,000
|
$93,144,000,000 | 5.40% |
| Structure Therapeutics Inc |
205.53%
2,200,000
|
$86,394,000,000 | 5.01% |
| Disc Medicine Inc |
Opened
1,850,000
|
$83,379,500,000 | 4.84% |
| Ocular Therapeutix Inc |
77.24%
10,300,000
|
$70,452,000,000 | 4.09% |
| Olema Pharmaceuticals, Inc. |
46.39%
6,417,750
|
$69,440,056,000 | 4.03% |
| Vera Therapeutics Inc |
230.43%
1,900,000
|
$68,742,000,000 | 3.99% |
| Moonlake Immunotherapeutics |
Opened
1,500,000
|
$65,955,000,000 | 3.83% |
| Janux Therapeutics Inc |
900.00%
1,500,000
|
$62,835,000,000 | 3.64% |
| Immunocore Hldgs Plc |
Closed
900,000
|
$58,500,000,000 | |
| Xencor Inc |
361.54%
3,000,000
|
$56,790,000,000 | 3.29% |
| Silence Therapeutics plc |
100.00%
2,952,122
|
$56,090,318,000 | 3.25% |
| Sarepta Therapeutics Inc |
25.00%
300,000
|
$47,400,000,000 | 2.75% |
| Akero Therapeutics Inc |
100.00%
1,600,000
|
$37,536,000,000 | 2.18% |
| Design Therapeutics Inc |
100.00%
10,065,002
|
$33,717,756,000 | 1.96% |
| Annexon Inc |
116.39%
6,600,000
|
$32,340,000,000 | 1.88% |
| Apellis Pharmaceuticals Inc |
No change
800,000
|
$30,688,000,000 | 1.78% |
| Immunovant Inc |
35.21%
1,150,000
|
$30,360,000,000 | 1.76% |
| Geron Corp. |
Closed
9,000,000
|
$29,700,000,000 | |
| Nuvalent Inc |
Opened
390,000
|
$29,585,400,000 | 1.72% |
| Xenon Pharmaceuticals Inc |
Opened
750,000
|
$29,242,500,000 | 1.70% |
| Ionis Pharmaceuticals Inc |
Opened
600,000
|
$28,596,000,000 | 1.66% |
| Stoke Therapeutics, Inc. |
Opened
2,100,000
|
$28,371,000,000 | 1.65% |
| Erasca Inc |
Opened
11,800,000
|
$27,848,000,000 | 1.62% |
| Enliven Therapeutics Inc |
24.41%
1,190,000
|
$27,810,300,000 | 1.61% |
| Celldex Therapeutics Inc. |
Closed
650,000
|
$27,280,500,000 | |
| Spyre Therapeutics Inc |
360.00%
1,150,000
|
$27,036,500,000 | 1.57% |
| Engene Holdings Inc |
200.00%
2,400,000
|
$22,632,000,000 | 1.31% |
| Cybin Inc |
100.00%
80,000,000
|
$21,680,000,000 | 1.26% |
| Skye Bioscience Inc |
Opened
2,603,036
|
$20,850,318,000 | 1.21% |
| Elevation Oncology Inc |
670.00%
7,700,000
|
$20,790,000,000 | 1.21% |
| Dyne Therapeutics, Inc. |
69.36%
530,000
|
$18,703,700,000 | 1.08% |
| Biohaven Ltd |
Opened
500,000
|
$17,355,000,000 | 1.01% |
| Relay Therapeutics, Inc. |
Opened
2,600,000
|
$16,952,000,000 | 0.98% |
| Trevi Therapeutics, Inc. |
154.55%
5,600,000
|
$16,688,000,000 | 0.97% |
| Rocket Pharmaceuticals Inc |
46.15%
700,000
|
$15,071,000,000 | 0.87% |
| COMPASS Pathways plc |
798.54%
2,318,060
|
$14,001,082,000 | 0.81% |
| Cg Oncology Inc |
Closed
300,000
|
$13,170,000,000 | |
| Kyverna Therapeutics Inc |
Closed
500,000
|
$12,420,000,000 | |
| Viridian Therapeutics Inc |
Closed
700,000
|
$12,257,000,000 | |
| Cullinan Oncology, LLC |
Closed
700,000
|
$11,928,000,000 | |
| Immatics N.v |
Closed
1,000,000
|
$10,510,000,000 | |
| Lineage Cell Therapeutics In |
50.40%
9,400,000
|
$9,374,620,000 | 0.54% |
| Atyr Pharma Inc |
93.55%
6,000,000
|
$9,360,000,000 | 0.54% |
| Praxis Precision Medicines I |
Closed
150,000
|
$9,153,000,000 | |
| Astria Therapeutics Inc |
19.68%
1,000,000
|
$9,100,000,000 | 0.53% |
| Syndax Pharmaceuticals Inc |
Closed
350,000
|
$8,330,000,000 | |
| Nextcure Inc |
159.74%
5,000,000
|
$7,950,000,000 | 0.46% |
| Cytokinetics Inc |
Closed
100,000
|
$7,011,000,000 | |
| Avalo Therapeutics Inc |
Opened
539,079
|
$6,722,315,000 | 0.39% |
| Kura Oncology Inc |
Closed
300,000
|
$6,399,000,000 | |
| Neumora Therapeutics Inc. |
56.93%
600,000
|
$5,898,000,000 | 0.34% |
| Allakos Inc |
100.00%
5,800,000
|
$5,800,000,000 | 0.34% |
| Adverum Biotechnologies Inc |
44.44%
833,332
|
$5,716,658,000 | 0.33% |
| Applied Therapeutics, Inc. |
11.11%
1,200,000
|
$5,323,800,000 | 0.31% |
| Cartesian Therapeutics Inc |
Opened
180,000
|
$4,861,800,000 | 0.28% |
| Rapport Therapeutics Inc |
Opened
208,910
|
$4,373,322,000 | 0.25% |
| Unicycive Therapeutics Inc |
100.00%
6,939,854
|
$3,477,560,000 | 0.20% |
| Tourmaline Bio Inc |
Closed
99,208
|
$2,271,863,000 | |
| Io Biotech Inc |
100.00%
987,654
|
$1,155,556,000 | 0.07% |
| Immunic, Inc. |
Closed
421,184
|
$555,963,000 | |
| Boundless Bio Inc |
41.10%
117,806
|
$433,114,000 | 0.03% |
| Leap Therapeutics Inc |
Closed
39,500
|
$105,070,000 | |
| No transactions found | |||
| Showing first 500 out of 65 holdings | |||
Hedge funds similar to Logos Global Management L.P.
- Azora Capital L.P.
- Smith Asset Management
- Ashton Thomas Private Wealth
- Altos Ventures Management
- Soma Equity Partners L.P.
- Darlington Partners Capital Management, L.P.
- Quintet Private Bank (europe) S.A.
- Sageview Advisory
- Standard Investments
- Cormorant Asset Management, L.P.
- Diversify Advisory Services
- Lmcg Investments
- Rbf Capital
- Jana Partners Management, L.P.